BACKGROUND AND AIMS: Bronchodilator reversibility (BDR) and inhaled corticosteroid (ICS) use were assessed for volunteers who responded to an advertisement requesting current or ex-smokers who were experiencing @entity1353 to attend for lung function testing. METHODS: One hundred and fifty-four volunteers responded. Forced expiratory volume (FEV1) was measured before and after 400 microg of @entity3045 . Significant BDR was assessed according to guidelines of: (i) the American @entity1514 Society (> or =12% plus 200 mL of baseline FEV1 or forced vital capacity), (ii) the British- @entity1514 Society (BTS) (> or =15% plus 200 mL of baseline FEV1), (iii) the European @entity1514 Society (> or =10% predicted FEV1), and (iv) the most commonly used criteria in Australia and New Zealand (> or =15% of baseline FEV1). RESULTS: One hundred and twenty-three subjects (33 female; 40 current smokers; median pack years 48 (range 5-144)) were suitable for analysis (i.e. had no history of @entity565 , demonstrable airflow limitation and a forced expiratory ratio (FER) of <70%). Twenty (16%) @entity1 had an FEV1 within the normal range but FER of <70%, 24 (20%) @entity1 had mild disease (FEV1 60-80% predicted), 31 (24%) @entity1 had moderate disease (FEV1 40-59% predicted), and 48 (39%) @entity1 had severe disease (FEV1 <40% predicted), according to BTS criteria. Significant BDR was evident in: (i) 58 (47%) subjects by American criteria, (ii) 26 (21%) subjects by British criteria, (iii) 19 (15%) subjects by European criteria and (iv) 36 (29%) subjects by Australasian criteria. ICS use was reported by 71 (58%) subjects overall and was weakly, but significantly, related to poorer FEV1 (r = -0.2; P < 0.01), and greater BDR (r = 0.3; P < 0.005). CONCLUSION: @entity1030 in Australian volunteers with no history of @entity565 encompasses many individuals with significant BDR. Interestingly, most volunteers reported ICS use and this was related to poorer spirometry and greater BDR. However, until the underlying immuno-pathology has been determined they cannot be assumed to have " @entity565 " or even an " @entity748 element".

Bronchodilator reversibility in Australian adults with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['breathlessness'] @entity3045 :: ('MESH:D000420', 'Chemical') :: ['salbutamol'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['Thoracic'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['Chronic obstructive pulmonary disease']
@entity1030 :: (MESH:D029424,Disease) :: ['chronic obstructive pulmonary disease']
